RONALD MCFADDEN: Open Payments
NPI 1285718734 · CLARION, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,044 in 109 payments from 14 companies in 2025. Trend: 2023 $29,616 · 2024 $19,286 · 2025 $2,044
Food & beverage: $1,966Education: $78
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 17 | $327 |
| ABBVIE INC. | 19 | $268 |
| Vanda Pharmaceuticals Inc. | 7 | $196 |
| Alkermes, Inc. | 13 | $186 |
| Neurocrine BioSciences, Inc. | 9 | $180 |
| Otsuka America Pharmaceutical, Inc. | 8 | $169 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $163 |
| Axsome Therapeutics, Inc. | 8 | $155 |
| Collegium Pharmaceutical, Inc. | 5 | $112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $91 |
Products named: VRAYLAR, REXULTI, ARISTADA, INGREZZA, FANAPT, UZEDY, CAPLYTA, Auvelity.
Industry payments across PA — which companies pay providers there.
